Aivita Launches Phase 2 Trial of Dendritic Cell Immunotherapy for Ovarian Cancer

Aivita Launches Phase 2 Trial of Dendritic Cell Immunotherapy for Ovarian Cancer
Aivita Biomedical has initiated a Phase 2 trial of a new kind of dendritic cell immunotherapy for certain types of ovarian cancer. The therapy uses a patient’s own dendritic cells, which are boosted to fight the tumor by exposure to tumor proteins. The trial is running at the Hoag Memorial Hospital Presbyterian in Newport Beach,

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *